Biosimilar Monoclonal Antibodies Market Opportunities Are Emerging Beyond Traditional Growth Areas
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Biosimilar Monoclonal Antibodies Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The biosimilar monoclonal antibodies market has experienced robust expansion over recent years. Its valuation is projected to rise from $10.64 billion in 2025 to $11.29 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historical growth has been driven by several key factors: the elevated expense of original biologic drugs, an increasing prevalence of chronic and autoimmune conditions, the expiration of patents for major monoclonal antibodies, rising healthcare spending, and the gradual establishment of clearer regulatory frameworks for biosimilars.
The biosimilar monoclonal antibodies industry is anticipated to experience robust expansion in the coming years. By 2030, its value is projected to hit $14.58 billion, achieving a compound annual growth rate (CAGR) of 6.6%. Several factors are driving this growth in the forecast period, including the broadening of biosimilar development initiatives, a heightened need for economical biologic treatments, growing authorizations in developing economies, progress in biopharmaceutical production methods, and favorable government measures encouraging biosimilar utilization. Noteworthy developments expected during this period involve the growing preference for cost-efficient biosimilar monoclonal antibodies, more frequent application of biosimilars in oncology and autoimmune conditions, rising confidence among healthcare professionals and patients regarding these products, an increase in regulatory clearances in international markets, and a heightened emphasis on broadening the availability of biologic therapies.
Download A Free Sample Report For Comprehensive Market Insights:
#Biosimilar Monoclonal Antibodies Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing prevalence of autoimmune conditions is set to boost the biosimilar monoclonal antibodies market. These disorders occur when the immune system erroneously attacks the body’s own tissues and organs. This increase largely stems from heightened exposure to environmental factors like pollution and chemicals, which disturb immune system equilibrium and spur irregular immune reactions. By delivering cost-effective, potent, and broadly available targeted treatments that control excessive immune activity in patients, biosimilar monoclonal antibodies play a crucial role in tackling this issue. In February 2024, Arthritis Australia, a nonprofit based in the country, reported that an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these figures anticipated to climb to roughly 280,040 males and 479,828 females by 2040. Consequently, the rising incidence of autoimmune diseases is fueling growth in the biosimilar monoclonal antibodies market.
Biosimilar Monoclonal Antibodies Market Segment Breakdown: Which Categories Generate The Most Revenue?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Biosimilar Monoclonal Antibodies Market Industry Trends: What Changes Are Reshaping Demand?
Leading firms within the biosimilar monoclonal antibody sector are actively creating biosimilar versions of the monoclonal antibody, aiming to deliver more affordable alternatives to original monoclonal antibody therapies, thereby enhancing healthcare access and cost-effectiveness. An intravenous formulation describes a preparation of the antibody meant for direct administration into the bloodstream via a vein to achieve a swift therapeutic effect. As an example, in May 2024, Bio-Thera Solutions, a biopharmaceutical company headquartered in China, along with Biogen Inc., a biopharmaceutical firm based in the United States, introduced TOFIDENCE (tocilizumab-bavi) in an intravenous formulation within the U.S. market. The U.S. Food and Drug Administration granted approval for TOFIDENCE in September 2023, targeting the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At the time of its launch, TOFIDENCE was made available in three vial sizes: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL for intravenous infusion, with subcutaneous formulations slated for introduction at a later date.
Biosimilar Monoclonal Antibodies Market Key Players And Strategic Industry Positioning
Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
Access The Complete Biosimilar Monoclonal Antibodies Market Report:
Biosimilar Monoclonal Antibodies Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
